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abstract
Due to the physicochemical properties of bile acids/salts (i.e., hydrophobic and ionizable), the application of
reverse-phase liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based methods are ideally suited
for the measurement of these compounds in a host of microbiologically-relevant matrices. Here, we provide a
detailed bioanalytical protocol that contains several modiﬁcations of a method previously described by Wegner
et al. [1]. Brieﬂy, this modiﬁed method exhibits the following advantages for the measurement of cholic acid
(CA), taurocholic acid (TCA), and deoxycholic acid (DCA) in microbiome-relevant sample matrices: i) fecal sample
processing has been streamlined by the elimination of lyophilization and manual homogenization steps; ii) the
Sciex 6500 QTRAP hybrid triple-quadrupole/linear ion trap mass spectrometer has suﬃcient sensitivity to perform
the measurement of bile acids/salts in negative ion mode – ammonium adducts of bile acids/salts are not required
for detection; and, iii) assay throughput has been boosted by more than 5-fold by shortening the chromatographic
duty cycle of a single sample injection from 45 min to 8.4 min. Recently, the method was used to perform 508
sequential injections (72 calibration standards, 52 blank-internal standard sample, and 368 MiniBioReactor Array
(MBRA)-derived samples) from four separate batches over a 4-day time period.
© 2020 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)
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Speciﬁcations Table

Subject Area:
More speciﬁc subject area:
Protocol name:
Reagents/tools:

Experimental design:

Trial registration:
Ethics:
Value of the Protocol:

Immunology and Microbiology
Microbiome-related research projects
Measurement of bile acids/salts in microbiome relevant matrices by LC-MS/MS
Materials
Optima LC/MS-grade water, methanol, and acetonitrile, and ACS reagent-grade,
absolute ethanol (200 proof) were from Thermo Fisher Scientiﬁc (Waltham,
MA, USA). Ammonium formate (99%), phosphate buffered saline (PBS), and
dimethyl sulfoxide (DMSO) were from Millipore Sigma (Billerica, MA, USA). The
authentic reference materials for sodium cholic acid (CA) and sodium
deoxycholic acid (DCA) were from Thermo Fisher Scientiﬁc, and sodium
taurocholic acid (TCA) was from Millipore Sigma. Authentic D4 -cholic acid
(D4 –CA) and D4 -deoxycholic acid (D4 -DCA) Internal Standard (IS) reference
materials were purchased from CDN Isotopes (Pointe-Claire, Quebec, Canada).
Polyvinyl diﬂuoride (PVDF) membrane ﬁlter plates with 0.2 μm pores were
from Thermo Fisher Scientiﬁc. High-Performance Liquid Chromatography
(HPLC) separations were performed using a Raptor C18 (2.7 μm superﬁcially
porous silica particle (SPP), 100 mm (L) x 2.1 mm (ID), 90 Å pore size; Cat
#9304A12) analytical column and an Ultra C18 (5.0 μm silica, 10 mm
(L) x 2.1 mm (ID), 100 Å pore size; Cat #917450212) guard column from Restek
(Bellefonte, PA, USA). MiniBioReactor Array (MBRA) devices were constructed
and used as described previously [11].
Biological Materials
The custom bioreactor medium used for this study has been described
previously [11]. The protocols for the harvesting and processing of bacterial
cells from human fecal communities used for this study were described
previously [11]. The protocols for the collection and processing of mouse fecal
pellets used for this study were described previously [12].
HPLC-tandem mass spectrometry (LC-MS/MS) System
The method was developed on an LC-MS/MS system comprised of the
following components: i) a Genius 3031 nitrogen generator by Peak Scientiﬁc
(Inchinnan, Scotland, UK); ii) a Security Plus uninterruptable power supply by
Powervar (Tustin, CA, USA); iii) a Nexera X2 MP HPLC system by Shimadzu
(Kyoto, Japan); iv) a Sciex 6500 QTRAP hybrid triple-quadrupole/linear ion trap
mass spectrometer by Danaher (Washington, DC, USA); and, v) a Dell Optiplex
XE2 personal computer that has been conﬁgured for LC-MS/MS instrument
control.
This method provides a detailed description of the materials, equipment, and
methods necessary for performing LC-MS/MS-based quantitative bioanalysis of
the CA, TCA, and DCA content of sample matrices pertinent to understanding
host-microbiome interactions.
N/A
N/A
Advantages of this method include:
1) Bile acids/salts are multifunctional compounds of great interest to the
microbiome-based research community.
2) LC-MS/MS-based methods can measure the bile acid/bile salt content in
bioreactor-derived broth media and stool samples
3) The method can be considered high-throughput – we are able to process up
to 192 MiniBioReactor Array (MBRA) or mouse fecal samples per 8 h day, and
can perform the instrumental analysis of these samples in a 36 h timeframe.

∗
Description of protocol: [This protocol contains reﬁned extraction, chromatographic, and MS/MS procedures that enhance
the analytical throughput of an existing quantitative LC-MS/MS-based bile acid/salt method [1]. The method modiﬁcations described
herein were necessary to accommodate the large sample counts associated with ongoing microbiome projects supported by the Texas
Children’s Microbiome Center–Mass Spectrometry Laboratory (TCMC-MSL). The procedural modiﬁcations yielded the following method
improvements: i) the acquisition duty cycle was reduced from 45 min to 8.4 mins per sample; ii) the processing rate was increased
to 192 samples per 8 h day; and, iii) chromatographic data for the deprotonated precursor ions of the bile acids/salts were measured
directly using the negative ionization mode of a Sciex 6500 QTRAP MS system, rather than measuring the ammoniated adducts of
bile acids/salts in positive ionization mode as previously reported [1].]
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Biochemical background
In the human liver, primary bile acids chenodeoxycholic acid (CDCA) and cholic acid (CA) are
formed by catabolism of cholesterol [2,3], and are conjugated to glycine and taurine to form the
hydrophilic bile salts glycocholic acid (GCA) and glycochenodeoxycholic acid (GCDCA), and taurocholic
acid (TCA) and taurochenodeoxycholic acid (TCDCA), respectively (Figure 1)[4,5]. After formation, bile
salts enter the enterohepatic cycle where they are: i) exported with other hydrophobic components
to form bile in the gall bladder [6]; ii) secreted into the duodenum where they aid in the absorption
and digestion of hydrophobic dietary components; and, iii) are reabsorbed (~95% of the pool) from the
chyme in the distal ileum and are transported back to the liver via the portal vein thus completing
a single revolution of the enterohepatic cycle [6]. In the human gut, a small proportion (~5%) of
the bile salt pool undergoes microbiota-mediated deconjugation of glycine and taurine to reform
the hydrophobic, cytotoxic, and potentially antimicrobial primary bile acids CDCA and CA [7–9], and
these compounds may be metabolized further to the secondary bile acids, deoxycholic acid (DCA) and
lithocholic acid (LCA) by microbiota in the large bowel [10].
Solution preparations
Internal standard (IS) solution preparations
1. Individual Internal Standard (IS) Stock Solutions for D4 -cholic acid (D4 –CA) and D4 -deoxycholic
acid (D4 -DCA) are each prepared at a concentration of ~10 mg/mL in Optima LC/MS-grade water
(grade of water used throughout the protocol), and in a solution of 1:2 dimethyl sulfoxide:
water, respectively. These solutions are stored frozen at −80 °C while not in use. Note: Free
D4 -DCA is relatively water insoluble, therefore it may be necessary to use a combination of vortexmixing (at 2000 RPM for 5 min) and gentle heating (at 70 °C for 1 min) in a block heater to
re-solubilize the bile acid/salt content in the freshly thawed stock solution preparations.
2. A Combined IS Intermediate Solution is prepared by diluting appropriate volumes of the D4 –CA
and D4 -DCA IS Stock Solutions in an appropriate volume of 1:1 methanol: water solution to
yield a concentration of 500 ng/mL for each compound in the combined solution. This solution
is refrigerated at +4 °C while not in use.
3. A Working IS-A (WIS-A) Solution is prepared by diluting a volume of Combined IS Intermediate
Solution in an equal volume of 1:1 methanol: water solution yielding a concentration of
250 ng/mL for each IS component (D4 –CA and D4 -DCA). This solution is refrigerated at +4 °C
while not in use, and is discarded after 1 week of storage. Note: This solution is used as the
diluent for all microbiome samples prior to analysis.
4. A Working IS-B (WIS-B) Solution is prepared by diluting a 9 mL volume of the WIS-A Solution
with a 1 mL volume of 1:1 methanol: water solution yielding a concentration of 225 ng/mL
for each IS component (D4 –CA and D4 -DCA). This solution is refrigerated at +4 °C while not
in use, and is discarded after 1 week of storage. Note: This solution is used as the diluent in the
preparation of the CA, DCA, and TCA containing Working Analyte Solution, and the serially-diluted
LC-MS/MS calibration standards.
Analyte solution preparations
1. Individual Analyte Stock Solutions for CA, DCA, and TCA are each prepared at a concentration
of ~100 mg/mL in water. These solutions are stored frozen at −80 °C while not in use. Note:
sodium salts of bile acids are readily water soluble, but it may still be necessary to re-solubilize
the bile acid/salt content in the stock solutions. A combination of vortex-mixing (at 2000 RPM for
5 min) and gentle heating (at 70 °C for 1 min) may be used to re-solubilize insoluble bile acid/salt
material.
2. A Combined Analyte Intermediate Solution is prepared by diluting appropriate volumes of
the CA, DCA, and TCA Analyte Stock Solutions in an appropriate volume of water to yield a
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Table 1
Serial dilution scheme for the preparation of the bile acid/salt Calibrators.
Calibrator

CA, DCA, and TCA
concentration in each
Calibrator (ng/mL)

Source Solution

Volume of
Source Solution
(μL)

F
E
D
C
B
A

10 0 0
250
62.5
15.6
3.90
0.977

Working Analyte Solution
F
E
D
C
B

10
100
100
100
100
100

Volume of
Working IS-B
Solution (μL)
990
300
300
300
300
300

concentration of 10.0 mg/mL for each compound in the combined solution. This solution is
sub-aliquotted at 100 μL volumes and stored frozen at −80 °C while not in use.
3 A Working Analyte Solution is prepared by diluting an appropriate volume of the Combined
Analyte Intermediate Solution in an appropriate volume of the WIS-B Solution to yield a
concentration of 100 μg/mL for each analyte component (CA, DCA, and TCA). This solution is
refrigerated at +4 °C while not in use, and is discarded after 1 week of storage.
4. The LC-MS/MS calibration standards (Calibrators) are prepared by serial dilution using the
Working Analyte Solution as the primary source solution and the WIS-B solution as the diluent
(See Table 1). These Calibrators are refrigerated at +4 °C while not in use, and are discarded
after 1 week of storage.
Microbiome sample preparation, shipment, and storage and handling conditions
Bioreactor sample collection, ﬁlter-sterilization, and extraction procedures
Bacterial cells from human fecal communities are grown in the bioreactor medium contained in
the MBRA devices [11]. Bioreactor medium contains bovine bile as a source of bile salts. Samples are
removed from communities and cells are pelleted by centrifugation at 30 0 0 g for 5 min. Clariﬁed
supernatants are ﬁltered through 0.2 μm polyvinyl diﬂuoride (PVDF) membrane ﬁlter plates by
centrifugation at 200 g for 5 min. Filtered samples are stored frozen at −80 °C while awaiting
shipment to the Texas Children’s Microbiome Center Mass Spectrometry Laboratory (TCMC-MSL).
Mouse stool collection, ﬁlter-sterilization, and extraction procedures
Fecal samples are collected from human microbiota associated mice and stored at −80 °C [12].
Fecal pellets (30–60 mg) are fully resuspended in a 250 μL volume of phosphate buffered saline
(PBS), and are centrifuged at 20,0 0 0 g for 1 min. The clariﬁed supernatant is transferred to a new
tube. Decanted fecal material is resuspended in a 250 μL volume of absolute ethanol (200 proof).
The ethanolic samples are centrifuged at 20,0 0 0 g for 1 min. Equal volumes of the clariﬁed ethanolic
and PBS supernatants are combined and ﬁltered through 0.2 μM PVDF membrane ﬁlter plates by
centrifugation at 200 g for 5 min. Filtered samples are stored frozen at −80 °C while awaiting
shipment to the TCMC-MSL.
Long-term sample storage and handling
1. Samples (bioreactor media or stool extracts) that are generated offsite are shipped to the TCMCMSL on dry ice, and upon receipt are transferred immediately into a −80 °C freezer for storage
until further processing and analysis may be performed. Samples that are generated in the
TCMC are ﬁlter-sterilized if needed, and are then transferred to a −80 °C freezer as soon as
possible.
2. All microbiome-derived samples are thawed at ambient temperature on the laboratory
benchtop.
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3. If samples are provided in 96-well plates, then the entire sample volume contained in each
well is transferred to individual 0.6 or 1.5 mL Eppendorf tubes, and processed further according
to the following protocols. All samples are vortex-mixed for 2 min using a multi-tube vortexer.
Stool sample extracts are centrifuged at 10,0 0 0 g for 10 min to settle the debris prior to sample
aliquoting and dilution. After sample processing has been completed for the entire batch, the
residual sample volumes contained in the Eppendorf tubes are stored frozen at −80 °C pending
re-analysis.

Sample dilution procedures
1000-fold sample dilutions for MBRA-derived bioreactor media samples
1. For this particular study, it was determined that a 10 0 0-fold dilution was suitable for the levels
of CA and DCA contained in the samples. Dilution factor suitability should be assessed for each
new study prior to sample analysis.
2. A 100-fold primary dilution is performed by mixing a 10 μL volume of the undiluted bioreactor
sample in a 990 μL volume of a 1:1 methanol: water solution. The diluted samples are then
vortex-mixed for 15 s.
3. A secondary sample dilution is performed directly in a polypropylene autosampler injection
vial by mixing a 10 μL volume of the 100-fold diluted bioreactor sample in 90 μL of the WIS-A
Solution for an overall dilution factor of 10 0 0-fold. The diluted sample is then vortex-mixed for
15 s, and a 5 μL volume of sample is injected onto the LC-MS/MS system. Note: The 10% dilution
of the WIS-A solution during sample preparation is accounted for in the preparation of the WIS-B IS
solution that is used in the preparation of the calibrators.

10-fold sample dilutions for stool (CA, DCA, and TCA) and MBRA-derived bioreactor (TCA only) samples
1. For this study, it was determined that a 10-fold dilution was suitable for the levels of TCA
contained in the MBRA-derived bioreactor samples, and for the CA, DCA, and TCA contained in
the mouse fecal samples. Dilution factor suitability should be assessed for each new study prior
to sample analysis.
2. A 10-fold dilution is performed directly in a polypropylene autosampler injection vial by mixing
a 10 μL volume of the undiluted bioreactor/stool extract sample in 90 μL of the WIS-A Solution.
The diluted sample is then vortex-mixed for 15 s, and a 5 μL volume of sample is injected onto
the LC-MS/MS system. Note: The 10% dilution of the WIS-A solution during sample preparation is
accounted for in the preparation of the WIS-B IS solution that is used in the preparation of the
calibrators.

LC-MS/MS method details
Mobile phase and needlewash solution preparations
1. The Mobile Phase A (MPA) Solution is prepared by dissolving 0.631 g of ammonium formate in
1 L of water in a 1 L HPLC solvent reservoir bottle. The MPA Solution is swirled vigorously to
ensure complete dissolution of the salt, and is stored well-closed at ambient room temperature
while not in use, and the solution is discarded after 1 month.
2. The Mobile Phase B (MPB) Solvent is pure Optima LC/MS-grade acetonitrile and is stored wellclosed at ambient room temperature while not in use. The pure solvent does not expire.
3. The Needlewash (NW) Solution is prepared by mixing equal parts of water and Optima LC/MSgrade methanol in an HPLC solvent reservoir bottle. The NW Solution swirled vigorously to
ensure complete mixing, is degassed via sonication, and is stored well-closed at ambient room
temperature while not in use. This solution does not expire.
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Fig. 1. Molecular structure, chemical formula, and molar mass for host-derived taurocholic acid (TCA), and microbiota-derived
cholic acid (CA) and deoxycholic acid (DCA) contained in fecal or bioreactor-derived broth media samples.[7]

Chromatographic method
1. Reverse-phase chromatography is performed using a Raptor C18 (2.7 μm SPP particles, 100 mm
(L) x 2.1 mm (ID), 90 Å pore size; Cat #9304A12) analytical column with an Ultra C18 (5.0 μm
silica, 10 mm (L) x 2.1 mm (ID) mm, 100 Å pore size; Cat #917450212) guard column installed.
2. The needle rinse program on the Nexera X2 MP Autosampler is speciﬁed to perform external
rinsing only both before and after aspiration of sample using 500 μL of NW Solution each time.
3. The chromatographic method includes a column temperature of 50 °C, an autosampler tray
temperature of 15 °C, a mobile phase ﬂowrate of 0.30 mL/min, and a gradient elution program
speciﬁed as follows: 0–4.50 min, 5–90% MPB; 4.50–5.50 min, 90% MPB; 5.50–5.60 min, 90%−5%
MPB; 5.60–8.00 min, 5% MPB; with an overall cycle time of 8.4 min per acquisition, and an
operational back pressure of ~220 0 psi at initial conditions. The 650 0 QTRAP divert valve was
enabled and speciﬁed to divert the chromatographic eluate according to the following program:
0–1.00 min, divert to waste (position B); 1.0 0–8.0 0 min, divert to MS source (position A); 8:00–
8.40 min, divert to waste (Position B).
4. The retention times have typically been 3.1 min for TCA, 3.6 min for CA, and 4.25 min for DCA
(Fig. 2).

Column eﬃciency characterization
The column eﬃciency characterization for the Raptor C18 analytical and Ultra C18 guard column
combination was performed by computing the pertinent experimental parameters from a mid-level
calibration standard (Calibrator D – prepared at 62.5 ng/mL for CA, DCA, and TCA, and 225 ng/mL
for the IS compounds, D4 –CA and D4 -DCA) using previously described methods [13]. Brieﬂy, the
height equivalent to a theoretical plate (HETP; Eq (1)) and the number of theoretical plates per
meter (N/m; Eq (2)) were calculated using the following experimental parameters for each analyte
and IS compound: i) full-width at ½ max for the chromatographic peaks (W1/2 ) in minutes; ii) the
chromatographic retention time (τ R ) in minutes; and, iii) the column length (L) speciﬁed in the units
of cm for the computation of HETP (Eq. (1)), and in the units of m for N/m (Eq. (2)). All experimental
parameters used to perform the column eﬃciency characterization have been tabulated in Table 2
below.
HET P

 cm 
plate


=

plates per meter

W1/2

2

∗ L (cm )

5.54 ∗ (τR )2

N
m

5.54 ∗ (τR )2
= 
2
W1/2 ∗ L (m )

(1)

(2)
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Fig. 2. (A-D) Extracted-Ion Chromatograms (XICs) for a calibration standard that contained 62.5 ng/mL of taurocholate (A),
cholate (B), deoxycholate (C), and 225 ng/mL for the internal standards D4 -cholate (D; green trace) and D4 -deoxycholate (D;
blue trace). (E-H) XIC chromatograms that illustrate the instrument Responses (counts per second (CPS) for taurocholate (E),
cholate (F), deoxycholate (G), and the internal standards (H) for a 10 0 0-fold diluted bioreactor media sample.

MS/MS acquisition method
R
1. The TurboIonSpray
electrospray ionization (ESI) probe is installed in the Turbo VTM ion source
and is operated with the following source conditions: ionization mode polarity: negative;
curtain gas (Cur): 20; TurboIonSprayTM voltage (IS): −4500 V; source temperature (TEM):
250 °C; Ion Source Gas 1 (GS1; nebulization gas): 40; Ion Source Gas 2 (GS2; heater gas): 50.

8
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Table 2
Column eﬃciency characterization using a mid-level calibrator prepared at 62.5 ng/mL for all analytes and 250 ng/mL for all IS
compounds.
Analyte / IS

MS/MS
transition

Column
Length (L;
cm)

Retention
Time (τ R;
min)

Full width at
half-max
(W1/2 ; mins)

HETP
(cm/plate)

CA
D4 –CA (IS)
DCA
D4 -DCA (IS)
TCA

407 > 343
411 > 347
391 > 345
395 > 349
514 > 124

10
10
10
10
10

3.56
3.56
4.23
4.22
3.04

0.035
0.031
0.040
0.039
0.031

0.0 0 017
0.0 0 014
0.0 0 016
0.0 0 015
0.0 0 019

Plates per
meter (N/m)
590,0 0 0
720,0 0 0
640,0 0 0
670,0 0 0
520,0 0 0

Table 3
The molecule-speciﬁc MS parameters for cholic acid, deoxycholic acid, and taurocholic acid.
Q1 (m/z)

Q3 (m/z)

Dwell Time (mS)

ID

Collision energy (CE) (V)

407.3
407.3
411.3
411.3
391.3
391.3
395.3
395.3
514.3
514.3

343.3
289.3
347.3
290.3
345.3
355.3
349.3
359.3
124.1
107.0

50
50
50
50
50
50
50
50
50
50

Cholic acid 407 > 343
Cholic acid 407 > 289
Cholic acid-D4 411 > 347
Cholic acid-D4 411 > 290
Deoxycholic acid 391 > 345
Deoxycholic acid 391 > 355
Deoxycholic acid-D4 395 > 349
Deoxycholic acid-D4 395 > 359
Taurocholic acid 514>124
Taurocholic acid 514 > 107

−47
−52
−47
−52
−47
−46
−47
−46
−64
−64

2. MS operational parameters include the following: collisionally activated dissociation (CAD) gas
pressure: “High”; declustering potential (DP): −40 V; entrance potential: −8 V; collision-cell
exit potential (CXP): −10 V; mass analyzer quadrupole 1 (Q1) resolution setting: unit; Q3
resolution: unit; molecule speciﬁc parameter for each bile acid analyte are tabulated in Table 3.
Method performance characteristics
A total of four analytical batches were prepared across two separate days – each batch consisted
of a calibration curve, 13 interspersed blanks, and 96 MBRA-derived media samples that had
been diluted according to the procedures described above. Calibration curves were constructed for
each analyte by plotting the instrument response (IR = Aanalyte / AIS ) factor of each Calibrator
against their respective nominal concentration. From this plot, a least-squares, linear regression with
weighting (1/x) was used to calculate the line of best ﬁt for each analyte, and yielded the following
representative calibration curves for each analyte: CA: IRCA = 0.00526∗ [CA] + 0.00651, R2 = 0.991;
TCA: IRTCA = 2310∗ [TCA] +3045, R2 = 0.9856; DCA: IRDCA = 0.00337∗ [DCA] + 0.00641, R2 = 0.999.
Limit of Detection (LOD) and Limit of Quantitation (LOQ) estimates were calculated using the standard
deviation of the y-intercepts and the mean slope of the four calibration curves calculated for each
analyte as described previously [14]. The LOD and LOQ estimates for each analyte are tabulated with
the mean linear regression parameters for the four calibration curves (± Standard Error of the Mean
(SEM)) in Table 4.
Discussion
Herein, we report on a high-throughput LC-MS/MS-based bioanalytical method that is suitable
for the quantitation of CA, TCA, and DCA in microbiome relevant matrices such as stool and ﬁltersterilized MBRA-derived bioreactor broth media. Using this method, TCMC-MSL staff are capable of
processing up to 192 stool or bioreactor samples in a single 8 h day, and the LC-MS/MS acquisition
of all calibrators, blanks, and unknown samples will require ~36 h to complete for the two analytical
batches. This method is highly adaptable, and with the purchase of authentic reference standards, can
be modiﬁed to include other bile acids/salts that may be of interest TCMC-MSL collaborators.
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Table 4
Mean weighted (1/x) linear regression parameters for cholic acid (CA), taurocholic acid (TCA), and deoxycholic acid (DCA)
calibration curves (n = 4) over a dynamic range of 0.977 to 10 0 0 ng/mL.
Analyte

Internal Standard
(IS)

LOD / LOQ
(ng/mL)

Slope (mean ±
SEM)

Y-intercept (mean
± SEM)

R2 (mean ± SEM)

CA
TCA∗
DCA

D4 –CA
–
D4 -DCA

0.20 / 0.63
0.76 / 2.3
1.1 / 3.4

0.00562 ± 1.8e−4
2410 ± 116
0.00359 ± 1.2e−4

0.0 060 0 ± 1.8e−4
2800 ± 280
0.00359 ± 1.2e−4

0.999 ± 1.8e−4
0.989 ± 1.3e−3
0.999 ± 1.0e−4

∗

A commercial source of D4 -TCA Internal Standard reference material was not found during development.
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